DOCSLIB.ORG

Volume 15 Johannes Zschocke K. Michael Gibson Garry Brown Eva Morava Verena Peters Editors

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Volume 15 Johannes Zschocke K. Michael Gibson Garry Brown Eva Morava Verena Peters Editors Johannes Zschocke K. Michael Gibson Garry Brown Eva Morava Verena Peters Editors JIMD Reports Volume 15 JIMD Reports Volume 15 . Johannes Zschocke • K. Michael Gibson Editors-in-Chief Garry Brown • Eva Morava Editors Verena Peters Managing Editor JIMD Reports Volume 15 Editor-in-Chief Editor Johannes Zschocke Eva Morava Division of Human Genetics Tulane University Medical School Medical University Innsbruck New Orleans Innsbruck Louisiana Austria USA Editor-in-Chief Managing Editor K. Michael Gibson Verena Peters WSU Division of Health Sciences Center for Child and Adolescent Clinical Pharmacology Unit Medicine Spokane Heidelberg University Hospital USA Heidelberg Germany Editor Garry Brown University of Oxford Department of Biochemistry Genetics Unit Oxford United Kingdom ISSN 2192-8304 ISSN 2192-8312 (electronic) ISBN 978-3-662-43750-6 ISBN 978-3-662-43751-3 (eBook) DOI 10.1007/978-3-662-43751-3 Springer Heidelberg New York Dordrecht London # SSIEM and Springer-Verlag Berlin Heidelberg 2015 This work is subject to copyright. All rights are reserved by the Publisher, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilms or in any other physical way, and transmission or information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed. Exempted from this legal reservation are brief excerpts in connection with reviews or scholarly analysis or material supplied specifically for the purpose of being entered and executed on a computer system, for exclusive use by the purchaser of the work. Duplication of this publication or parts thereof is permitted only under the provisions of the Copyright Law of the Publisher’s location, in its current version, and permission for use must always be obtained from Springer. Permissions for use may be obtained through RightsLink at the Copyright Clearance Center. Violations are liable to prosecution under the respective Copyright Law. The use of general descriptive names, registered names, trademarks, service marks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use. While the advice and information in this book are believed to be true and accurate at the date of publication, neither the authors nor the editors nor the publisher can accept any legal responsibility for any errors or omissions that may be made. The publisher makes no warranty, express or implied, with respect to the material contained herein. Printed on acid-free paper Springer is part of Springer Science+Business Media (www.springer.com) Contents 4-Hydroxyglutamate Is a Biomarker for Primary Hyperoxaluria Type 3 .......... 1 James J Pitt, Frank Willis, Nicholas Tzanakos, Ruth Belostotsky, and Yaacov Frishberg Excellent Response to a Ketogenic Diet in a Patient with Alternating Hemiplegia of Childhood .......................................................... 7 Anne Roubergue, Bertrand Philibert, Agne`s Gautier, Alice Kuster, Karine Markowicz, Thierry Billette de Villemeur, Sandrine Vuillaumier-Barrot, Sophie Nicole, Emmanuel Roze, and Diane Doummar Thiamine-Responsive and Non-responsive Patients with PDHC-E1 Deficiency: A Retrospective Assessment............................................... 13 Sanne van Dongen, Ruth M. Brown, Garry K. Brown, David R. Thorburn, and Avihu Boneh Diagnostic Exome Sequencing and Tailored Bioinformatics of the Parents of a Deceased Child with Cobalamin Deficiency Suggests Digenic Inheritance of the MTR and LMBRD1 Genes ......................................... 29 Kelly D. Farwell Gonzalez, Xiang Li, Hsiao-Mei Lu, Hong Lu, Joan E. Pellegrino, Ryan T. Miller, Wenqi Zeng, and Elizabeth C. Chao Report of Two Never Treated Adult Sisters with Aromatic L-Amino Acid Decarboxylase Deficiency: A Portrait of the Natural History of the Disease or an Expanding Phenotype? ............................................ 39 Vincenzo Leuzzi, Mario Mastrangelo, Agata Polizzi, Cristiana Artiola, Andre´ B.P. van Kuilenburg, Carla Carducci, Martino Ruggieri, Rita Barone, Barbara Tavazzi, Nico G.G.M. Abeling, Lida Zoetekouw, Vito Sofia, Mario Zappia, and Claudia Carducci Lysine-Restricted Diet as Adjunct Therapy for Pyridoxine-Dependent Epilepsy: The PDE Consortium Consensus Recommendations ......................... 47 Clara D.M. van Karnebeek, Sylvia Stockler-Ipsiroglu, Sravan Jaggumantri, Birgit Assmann, Peter Baxter, Daniela Buhas, Levinus A. Bok, Barbara Cheng, Curtis R. Coughlin II, Anibh M. Das, Alette Giezen, Wahla Al-Hertani, Gloria Ho, Uta Meyer, Philippa Mills, Barbara Plecko, Eduard Struys, Keiko Ueda, Monique Albersen, Nanda Verhoeven, Sidney M. Gospe Jr, Renata C. Gallagher, Johan K.L. Van Hove, and Hans Hartmann Mortality in Patients with Morquio Syndrome A ............................ 59 Christine Lavery and Chris Hendriksz v vi Contents Neurogenic Bladder Dysfunction Presenting as Urinary Retention in Neuronopathic Gaucher Disease ......................................... 67 Erin R. McNamara, Jennifer Sullivan, Shashi K. Nagaraj, John S. Wiener, and Priya S. Kishnani Common and Novel TMEM70 Mutations in a Cohort of Italian Patients with Mitochondrial Encephalocardiomyopathy.................................. 71 Daria Diodato, Federica Invernizzi, Eleonora Lamantea, Gigliola Fagiolari, Rossella Parini, Francesca Menni, Giancarlo Parenti, Lina Bollani, Elisabetta Pasquini, Maria A. Donati, Denise Cassandrini, Filippo M. Santorelli, Tobias B. Haack, Holger Prokisch, Daniele Ghezzi, Costanza Lamperti, and Massimo Zeviani Newborn Screening for Galactosemia in the United States: Looking Back, Looking Around, and Looking Ahead ..................................... 79 Brook M. Pyhtila, Kelly A. Shaw, Samantha E. Neumann, and Judith L. Fridovich-Keil Phenotypic Variability in Patients with Fanconi–Bickel Syndrome with Identical Mutations ........................................................... 95 Elena Fridman, Avraham Zeharia, Tal Markus-Eidlitz, and Yishai Haimi Cohen Successful Management of Enzyme Replacement Therapy in Related Fabry Disease Patients with Severe Adverse Events by Switching from Agalsidase Beta ® ® (Fabrazyme ) to Agalsidase Alfa (Replagal ) .............................. 105 Kazuya Tsuboi, Hiroshi Yamamoto, Fuji Somura, and Hiromi Goto Deep Brain Stimulation and Dantrolene for Secondary Dystonia in X-Linked Adrenoleukodystrophy ................................................ 113 Clara van Karnebeek, Gabriella Horvath, Tyler Murphy, Jacqueline Purtzki, Kristin Bowden, Sandra Sirrs, Christopher R. Honey, and Sylvia Stockler Cirrhosis and Liver Failure: Expanding Phenotype of Acid Sphingomyelinase- Deficient Niemann-Pick Disease in Adulthood.............................. 117 Olivier Lidove, Fre´de´ric Sedel, Fre´de´ric Charlotte, Roseline Froissart, and Marie T. Vanier Dried Blood Spots Allow Targeted Screening to Diagnose Mucopolysaccharidosis and Mucolipidosis.................................................... 123 Paulina Nieves Cobos, Cordula Steglich, Rene´ Santer, Zoltan Lukacs, and Andreas Gal Erratum to: Newborn Screening for Galactosemia in the United States: Looking Back, Looking Around, and Looking Ahead........................ 133 Brook M. Pyhtila, Kelly A. Shaw, Samantha E. Neumann, and Judith L. Fridovich-Keil JIMD Reports DOI 10.1007/8904_2013_291 RESEARCH REPORT 4-Hydroxyglutamate Is a Biomarker for Primary Hyperoxaluria Type 3 James J Pitt • Frank Willis • Nicholas Tzanakos • Ruth Belostotsky • Yaacov Frishberg Received: 22 April 2013 /Revised: 09 November 2013 /Accepted: 25 November 2013 /Published online: 22 February 2014 # SSIEM and Springer-Verlag Berlin Heidelberg 2014 Abstract Primary hyperoxaluria type 3 (PH3) is a recently Its measurement was readily incorporated into an existing identified inborn error of 4-hydroxyproline metabolism multi-analyte panel for comprehensive screening for inborn causing kidney stone disease. Diagnosis to date has relied errors of metabolism. There was a steady decline with age on mutation detection. The excretion of 4-hydroxygluta- in 4OHGlu levels, expressed as mmol/mmol of creatinine, mate (4OHGlu) was investigated in controls and a cohort of in controls. Levels in patients with PH3 ranged from 6.5 to nine patients with PH3 and their parents using flow 98 mmol/mmol of creatinine and were all significantly injection tandem mass spectrometry. 4OHGlu was stable increased when compared to age-matched controls (<4.2). in acidified urine samples and was not influenced by diet. Levels in eight parents (obligatory carriers of the corresponding mutation) were moderately, but significantly increased, ranging from 0.6 to 2.5 (age-matched controls Communicated by: Rodney Pollitt, PhD <1.4, p ¼ 0.03). Urine 4OHGlu screening was used to Competing interests: None declared prospectively diagnose PH3 in an 18-month-old boy with Electronic supplementary material: The online version of this calcium oxalate kidney stone disease associated with chapter (doi:10.1007/8904_2013_291) contains supplementary hyperoxaluria. 4OHGlu was also increased in a stored material, which is available to authorized users. : newborn screening dried blood spot sample from this child J.J. Pitt N. Tzanakos (37 mmol/L, controls <2.53). 4OHGlu testing provides a Victorian Clinical Genetics Services, Murdoch Childrens Research robust
Load more

Recommended publications
  • Clinical Applications and Implications of Common and Founder Mutations in Indian Subpopulations
    REVIEW OFFICIAL JOURNAL Clinical Applications and Implications of Common and Founder Mutations in Indian Subpopulations www.hgvs.org Arunkanth Ankala,1∗ † Parag M. Tamhankar,2 † C. Alexander Valencia,3,4 Krishna K. Rayam,5 Manisha M. Kumar,5 and Madhuri R. Hegde1 1Department of Human Genetics, Emory University School of Medicine, Atlanta, Georgia; 2ICMR Genetic Research Center, National Institute for Research in Reproductive Health, Mumbai, Maharashtra, India; 3Division of Human Genetics, Cincinnati Children’s Hospital Medical Center, Cincinnati, Ohio; 4Department of Pediatrics, University of Cincinnati Medical School, Cincinnati, Ohio; 5Department of Biosciences, CMR Institute of Management Studies, Bangalore, Karnataka, India Communicated by Arupa Ganguly Received 24 October 2013; accepted revised manuscript 16 September 2014. Published online 27 November 2014 in Wiley Online Library (www.wiley.com/humanmutation). DOI: 10.1002/humu.22704 that include a lack of widespread awareness about genetic disorders in the general population and the scarcity of specialized medical ABSTRACT: South Asian Indians represent a sixth of the world’s population and are a racially, geographically, and professionals and affordable genetic tests. Seeking a molecular di- genetically diverse people. Their unique anthropological agnosis and understanding the risk estimates are critical to making structure, prevailing caste system, and ancient religious sound reproductive choices, especially in families with an affected practices have all impacted the genetic composition of most individual. Adding to this adversity is the absence of a properly func- of the current-day Indian population. With the evolving tioning social health care system and insufficient encouragement socio-religious and economic activities of the subsects and of individual health insurance by the government.
    [Show full text]
  • Fructose As an Endogenous Toxin
    HEPATOCYTE MOLECULAR CYTOTOXIC MECHANISM STUDY OF FRUCTOSE AND ITS METABOLITES INVOLVED IN NONALCOHOLIC STEATOHEPATITIS AND HYPEROXALURIA By Yan (Cynthia) Feng A thesis submitted in the conformity with the requirements for the degree of Master of Science Graduate Department of Pharmaceutical Sciences University of Toronto © Copyright by Yan (Cynthia) Feng 2010 ABSTRACT HEPATOCYTE MOLECULAR CYTOTOXIC MECHANISM STUDY OF FRUCTOSE AND ITS METABOLITES INVOLVED IN NONALCOHOLIC STEATOHEPATITIS AND HYPEROXALURIA Yan (Cynthia) Feng Master of Science, 2010 Department of Pharmaceutical Sciences University of Toronto High chronic fructose consumption is linked to a nonalcoholic steatohepatitis (NASH) type of hepatotoxicity. Oxalate is the major endpoint of fructose metabolism, which accumulates in the kidney causing renal stone disease. Both diseases are life-threatening if not treated. Our objective was to study the molecular cytotoxicity mechanisms of fructose and some of its metabolites in the liver. Fructose metabolites were incubated with primary rat hepatocytes, but cytotoxicity only occurred if the hepatocytes were exposed to non-toxic amounts of hydrogen peroxide such as those released by activated immune cells. Glyoxal was most likely the endogenous toxin responsible for fructose induced toxicity formed via autoxidation of the fructose metabolite glycolaldehyde catalyzed by superoxide radicals, or oxidation by Fenton’s hydroxyl radicals. As for hyperoxaluria, glyoxylate was more cytotoxic than oxalate presumably because of the formation of condensation product oxalomalate causing mitochondrial toxicity and oxidative stress. Oxalate toxicity likely involved pro-oxidant iron complex formation. ii ACKNOWLEDGEMENTS I would like to dedicate this thesis to my family. To my parents, thank you for the sacrifices you have made for me, thank you for always being there, loving me and supporting me throughout my life.
    [Show full text]
  • Antenatal Diagnosis of Inborn Errors Ofmetabolism
    816 ArchivesofDiseaseinChildhood 1991;66: 816-822 CURRENT PRACTICE Arch Dis Child: first published as 10.1136/adc.66.7_Spec_No.816 on 1 July 1991. Downloaded from Antenatal diagnosis of inborn errors of metabolism M A Cleary, J E Wraith The introduction of experimental treatment for Sample requirement and techniques used in lysosomal storage disorders and the increasing prenatal diagnosis understanding of the molecular defects behind By far the majority of antenatal diagnoses are many inborn errors have overshadowed the fact performed on samples obtained by either that for many affected families the best that can amniocentesis or chorion villus biopsy. For be offered is a rapid, accurate prenatal diag- some disorders, however, the defect is not nostic service. Many conditions remain at best detectable in this material and more invasive only partially treatable and as a consequence the methods have been applied to obtain a diagnos- majority of parents seek antenatal diagnosis in tic sample. subsequent pregnancies, particularly for those disorders resulting in a poor prognosis in terms of either life expectancy or normal neurological FETAL LIVER BIOPSY development. Fetal liver biopsy has been performed to The majority of inborn errors result from a diagnose ornithine carbamoyl transferase defi- specific enzyme deficiency, but in some the ciency and primary hyperoxaluria type 1. primary defect is in a transport system or Glucose-6-phosphatase deficiency (glycogen enzyme cofactor. In some conditions the storage disease type I) could also be detected by biochemical defect is limited to specific tissues this method. The technique, however, is inva- only and this serves to restrict the material avail- sive and can be performed by only a few highly able for antenatal diagnosis for these disorders.
    [Show full text]
  • Severe Child Form of Primary Hyperoxaluria Type 2
    Konkoľová et al. BMC Medical Genetics (2017) 18:59 DOI 10.1186/s12881-017-0421-8 CASE REPORT Open Access Severe child form of primary hyperoxaluria type 2 - a case report revealing consequence of GRHPR deficiency on metabolism Jana Konkoľová1,2*, Ján Chandoga1,2, Juraj Kováčik3, Marcel Repiský2, Veronika Kramarová2, Ivana Paučinová3 and Daniel Böhmer1,2 Abstract Background: Primary hyperoxaluria type 2 is a rare monogenic disorder inherited in an autosomal recessive pattern. It results from the absence of the enzyme glyoxylate reductase/hydroxypyruvate reductase (GRHPR). As a consequence of deficient enzyme activity, excessive amounts of oxalate and L-glycerate are excreted in the urine, and are a source for the formation of calcium oxalate stones that result in recurrent nephrolithiasis and less frequently nephrocalcinosis. Case presentation: We report a case of a 10-month-old patient diagnosed with urolithiasis. Screening of inborn errors of metabolism, including the performance of GC/MS urine organic acid profiling and HPLC amino acid profiling, showed abnormalities, which suggested deficiency of GRHPR enzyme. Additional metabolic disturbances observed in the patient led us to seek other genetic determinants and the elucidation of these findings. Besides the elevated excretion of 3-OH-butyrate, adipic acid, which are typical marks of ketosis, other metabolites such as 3- aminoisobutyric acid, 3-hydroxyisobutyric acid, 3-hydroxypropionic acid and 2-ethyl-3-hydroxypropionic acids were observed in increased amounts in the urine. Direct sequencing of the GRHPR gene revealed novel mutation, described for the first time in this article c.454dup (p.Thr152Asnfs*39) in homozygous form. The frequent nucleotide variants were found in AGXT2 gene.
    [Show full text]
  • Increased Prevalence of Hereditary Metabolic Diseases Among Native Indians in Manitoba and Northwestern Ontario
    CLINICAL AND COMMUNITY STUDIES ETUDES CLINIQUES ET COMMUNAUTAIRES Increased prevalence of hereditary metabolic diseases among native Indians in Manitoba and northwestern Ontario James C. Haworth, MD, FRCPC; Louise A. Dilling, ART; Lorne E. Seargeant, PhD Objective: To compare the prevalence of hereditary metabolic diseases in the native and non-native populations of Manitoba and northwestern Ontario. Design: Retrospective analysis. Setting: Children's Hospital, Winnipeg. Patients: Patients were selected by three methods: laboratory tests designed to screen patients suspected of having a metabolic disease, laboratory investigation of newborn infants with abnormalities detected through screening, and investigation of near relatives of probands with disease. Results: A total of 138 patients with organic acid, amino acid and carbohydrate disorders were seen from 1960 to 1990. Of these, 49 (36%) were native Indians (Algonkian linguistic group). This was in sharp contrast to the proportion of native Indians in the total study population (5.8%). Congenital lactic acidosis due to pyruvate carboxylase deficiency (13 patients), glutaric aciduria type I (14 patients) and primary hyperoxaluria type II (8 patients) were the most common disorders detected. Other rare disorders included glutaric aciduria type II (one patient), 2-hydroxyglutaric aciduria (one patient) and sarcosinemia (one patient). Underreporting, especially of glutaric aciduria type I and hyperoxaluria type II, was likely in the native population. Conclusions: Hereditary metabolic diseases are greatly overrepresented in the native population of Manitoba and northwestern Ontario. We recommend that native children who present with illnesses involving disturbances of acid-base balance or with neurologic, renal or liver disease of unknown cause be investigated for a possible metabolic disorder.
    [Show full text]
  • SSIEM Classification of Inborn Errors of Metabolism 2011
    SSIEM classification of Inborn Errors of Metabolism 2011 Disease group / disease ICD10 OMIM 1. Disorders of amino acid and peptide metabolism 1.1. Urea cycle disorders and inherited hyperammonaemias 1.1.1. Carbamoylphosphate synthetase I deficiency 237300 1.1.2. N-Acetylglutamate synthetase deficiency 237310 1.1.3. Ornithine transcarbamylase deficiency 311250 S Ornithine carbamoyltransferase deficiency 1.1.4. Citrullinaemia type1 215700 S Argininosuccinate synthetase deficiency 1.1.5. Argininosuccinic aciduria 207900 S Argininosuccinate lyase deficiency 1.1.6. Argininaemia 207800 S Arginase I deficiency 1.1.7. HHH syndrome 238970 S Hyperammonaemia-hyperornithinaemia-homocitrullinuria syndrome S Mitochondrial ornithine transporter (ORNT1) deficiency 1.1.8. Citrullinemia Type 2 603859 S Aspartate glutamate carrier deficiency ( SLC25A13) S Citrin deficiency 1.1.9. Hyperinsulinemic hypoglycemia and hyperammonemia caused by 138130 activating mutations in the GLUD1 gene 1.1.10. Other disorders of the urea cycle 238970 1.1.11. Unspecified hyperammonaemia 238970 1.2. Organic acidurias 1.2.1. Glutaric aciduria 1.2.1.1. Glutaric aciduria type I 231670 S Glutaryl-CoA dehydrogenase deficiency 1.2.1.2. Glutaric aciduria type III 231690 1.2.2. Propionic aciduria E711 232000 S Propionyl-CoA-Carboxylase deficiency 1.2.3. Methylmalonic aciduria E711 251000 1.2.3.1. Methylmalonyl-CoA mutase deficiency 1.2.3.2. Methylmalonyl-CoA epimerase deficiency 251120 1.2.3.3. Methylmalonic aciduria, unspecified 1.2.4. Isovaleric aciduria E711 243500 S Isovaleryl-CoA dehydrogenase deficiency 1.2.5. Methylcrotonylglycinuria E744 210200 S Methylcrotonyl-CoA carboxylase deficiency 1.2.6. Methylglutaconic aciduria E712 250950 1.2.6.1. Methylglutaconic aciduria type I E712 250950 S 3-Methylglutaconyl-CoA hydratase deficiency 1.2.6.2.
    [Show full text]
  • Download Download
    jrenhep.com codonpublications.com REVIEW ARTICLE Liver Transplantation for Monogenic Metabolic Diseases Involving the Kidney Maurizio Salvadori1, Aris Tsalouchos2 1Renal Unit Careggi University Hospital, Viale Pieraccini, Florence, Italy; 2Division of Nephrology, Azienda Ospedaliera Careggi, Largo Alessandro Brambilla, Florence, Italy Abstract Several metabolic monogenic diseases may be cured by liver transplantation alone (LTA) or by combined liver–kidney transplan- tation (CLKT) when the metabolic disease has caused end-stage renal disease. Liver transplantation may be regarded as a substi- tute for an injured liver or as supplying a tissue that may replace a mutant protein. Two groups of diseases should be distinguished. In the first group, the kidney tissue may be severely damaged while the liver tissue is almost normal. In this group, renal transplan- tation is recommended according to the degree of renal damage and liver transplantation is essential as a genetic therapy for correcting the metabolic disorder. In the second group, the liver parenchymal damage is severe. In this group, liver transplanta- tion is essential to avoid liver failure. LTA may also avoid the progression of the renal disease; otherwise a CLKT is needed. In this review, we describe monogenic metabolic diseases involving the kidney that may have beneficial effects from LTA or CLKT. We also highlight the limitations of such procedures and the choice of alternative medical conservative treatments. Keywords: atypical hemolytic uremic syndrome; glycogen storage disease; monogenic metabolic diseases; organic acidurias; primary hyperoxaluria Received: 23 May 2017; Accepted after revision: 26 June 2017; Published: 19 July 2017. Author for correspondence: Maurizio Salvadori, Renal Unit Careggi University Hospital, Viale Pieraccini, 18, 50139, Florence, Italy.
    [Show full text]
  • 43 Primary Hyperoxalurias
    43 Primary Hyperoxalurias Pierre Cochat, Marie-Odile Rolland 43.1 Primary Hyperoxaluria Type 1 – 541 43.1.1 Clinical Presentation – 541 43.1.2 Metabolic Derangement – 542 43.1.3 Genetics – 542 43.1.4 Diagnosis – 542 43.1.5 Treatment and Prognosis – 542 43.2 Primary Hyperoxaluria Type 2 – 545 43.2.1 Clinical Presentation – 545 43.2.2 Metabolic Derangement – 545 43.2.3 Genetics – 545 43.2.4 Diagnosis – 545 43.2.5 Treatment and Prognosis – 545 43.3 Non-Type 1 Non-Type 2 Primary Hyperoxaluria – 545 References – 545 540 Chapter 43 · Primary Hyperoxalurias Oxalate Metabolism Oxalate is a poorly soluble end-product of the metabo- verted into oxalate by lactic acid dehydrogenase (LDH); lism of a number of amino acids, particularly glycine, it can also be converted into glycolate by glyoxylate and of other compounds such as sugars and ascorbic reductase (GR) and into glycine by glutamate: glyo- acid. The immediate precursors of oxalate are glyo- xylate aminotransferase (GGT). Glycolate can also xylate and glycolate (. Fig. 43.1). The main site of syn- be formed from hydroxypyruvate, a catabolite of glu- thesis of glyoxylate and oxalate is the liver peroxisome, cose and fructose. Hydroxypyruvate can be con- which can also detoxify glyoxylate by reconversion into verted into L-glycerate by LDH and into D-glycerate glycine, catalyzed by alanine: glyoxylate aminotrans- by hydroxypyruvate reductase (HPR), which also has ferase (AGT). In the cytosol, glyoxylate can be con - a GR activity. X . Fig. 43.1. Major reactions involved in oxalate, glyoxylate and HPR, hydroxypyruvate reductase; LDH, lactate dehydrogenase; glycolate metabolism in the human hepatocyte.
    [Show full text]
  • Inherited Enzyme Defects: a Review
    J Clin Pathol: first published as 10.1136/jcp.16.4.293 on 1 July 1963. Downloaded from J. clin. Path. (1963), 16, 293 Inherited enzyme defects: a review T. HARGREAVES' From the Department of Chemical Pathology, St. George's Hospital Medical School, Hyde Park Corner, London, S. W.I Sir Archibald Garrod in 1909 pointed out that four The consequences of a genetic change and an diseases, albinism, alkaptonuria. cystinuria, and alteration in the quality or quantity of a protein will pentosuria, were present from birth, lasted through- depend on the role normally subserved by that out life without worsening or improvement, and protein; in the cases that we are considering this is were present in other members of the family (Garrod, derangement of enzymatic function. The derange- 1909). These diseases were described as 'inborn errors ments that can occur include a blocked metabolic of metabolism'. The original four diseases have sequence. In the reaction A---* B-- C--# D, if been expanded to over 50 and the actual site of the C--# D is blocked then a clinical disorder may biochemical abnormality has been elucidated in many result from a failure to produce D, e.g., hypo- of them. In this review we shall consider those glycaemia due to an inability to form glucose from diseases which are either known or thought to be glucose-6-phosphate in von Gierke's disease. The due to single enzyme defects. We have not con- precursor C may accumulate; for example, bilirubin sidered those diseases that are thought to be due to accumulates in the absence of glucuronyl transferase.
    [Show full text]
  • Primary Hyperoxaluria: a Rare but KY Lo Important Cause of Nephrolithiasis SK Mak ELK Law !"#$%&'()*+,-./012
    MEDICAL PRACTICE PN Wong GMW Tong Primary hyperoxaluria: a rare but KY Lo important cause of nephrolithiasis SK Mak ELK Law !"#$%&'()*+,-./012 AKM Wong ○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○○ We report on a middle-aged man with end-stage renal failure apparently secondary to recurrent renal stones. He developed systemic oxalosis soon after commencing dialysis. The diagnosis of primary hyperoxaluria type 1 was supported by the finding of high dialysate glycolate excretion. The patient subsequently received an isolated cadaveric renal transplant, but the outcome was a rapid recurrence of oxalosis and early graft failure. Although isolated liver or renal transplantation in addition to various adjuvant measures may be considered in the early stage, combined liver- kidney transplantation remains the only definitive therapy for a patient with end-stage renal failure and systemic oxalosis due to hyperoxaluria type 1. This case illustrates the possible late presentation of primary hyperoxaluria type 1 and the poor outcome with isolated renal transplantation after the development of systemic oxalosis. One should thus have a high index of sus- picion in patients with recurrent renal stones of this rare, but nevertheless important, entity. !"#$%&'#()*+,-./01234%56/07859:;' !"#$%&'()*+,-./0123456789: !;<=0> !"#$%&'()*+,-./012345678#9:/;<=> !"#$%&'()*+,-./0123456789:;<=> !"#$%&'()*+,-./0 "#$123456789:;<= !"#$%&'()*+,-./.0123456789:;<=>1 !"#$%&'()*+,-.!/012345#$%678(/9:; !"#$%&'()*+,-.$/0123456)789:;<=> ! Introduction Key words: Hyperoxaluria,
    [Show full text]
  • Primary Hyperoxaluria Type III – a Model for Studying
    Primary hyperoxaluria type III – a model for studying perturbations in glyoxylate metabolism Ruth Belostotsky 1, James Jonathon Pitt 2 and Yaacov Frishberg 1, 3 1 Division of Pediatric Nephrology, Shaare Zedek Medical Center, Jerusalem, Israel. 2 VCGS Pathology, Murdoch Childrens Research Institute, Royal Children’s Hospital, Parkville, Victoria. Australia. 3Hadassah-Hebrew University School of Medicine, Jerusalem, Israel. Abstract word counter: 224 Text word count: 3622 Corresponding Author: Ruth Belostotsky, Division of Pediatric Nephrology, Shaare Zedek Medical Center, P.O.Box 3235, Jerusalem 91031, Israel; Tel: 972-2-6666749; Fax: 972-2- 6555484; e-mail: [email protected] 1 Abstract Perturbations in glyoxylate metabolism lead to the accumulation of oxalate and give rise to primary hyperoxalurias, recessive disorders characterized by kidney stone disease. Loss-of- function mutations in HOGA1 (formerly DHDPSL) are responsible for primary hyperoxaluria type III. HOGA1 is a mitochondrial 4-hydroxy-2-oxoglutarate aldolase catalyzing the fourth step in the hydroxyproline pathway. We investigated hydroxyproline metabolites in the urine of patients with primary hyperoxaluria type III using gas chromatography – mass spectroscopy. Significant increases in concentrations of 4-hydroxy- 2-oxoglutarate and its precursor and derivative 4-hydroxyglutamate and 2,4- dihydroxyglutarate, respectively, were found in all patients as compared to carriers of the corresponding mutations or healthy controls. Despite a functional block in the conversion of hydroxyproline to glyoxylate - the immediate precursor of oxalate - the production of oxalate increases. To explain this apparent contradiction we propose a model of glyoxylate compartmentalization in which cellular glyoxylate is normally prevented from contact with the cytosol where it can be oxidized to oxalate.
    [Show full text]
  • Transplantation for Primary Hyperoxaluria Type 1: Designing New Strategies in the Era of Promising Therapeutic Perspectives
    REVIEW Transplantation for Primary Hyperoxaluria Type 1: Designing New Strategies in the Era of Promising Therapeutic Perspectives Arnaud Devresse1,2, Pierre Cochat3,4, Nathalie Godefroid2,5 and Nada Kanaan1,2 1Division of Nephrology, Cliniques Universitaires Saint-Luc, Brussels, Belgium; 2Institut de Recherche Expérimentale et Clin- ique, Université Catholique de Louvain, Brussels, Belgium; 3Service de Néphrologie Rhumatologie Dermatologie Pédiatriques, Centre de Référence des Maladies Rénales Rares, Hôpital Femme-Mère-Enfant, Hospices Civils de Lyon et Université Claude- Bernard Lyon 1, Lyon, France; 4EPICIME Epidémiologie Pharmacologie Investigation Clinique Information Médicale de l’Enfant, Hospices Civils de Lyon, Lyon, France; and 5Division of Pediatric Nephrology, Cliniques Universitaires Saint-Luc, Brussels, Belgium Primary hyperoxaluria type 1 (PH1) is an autosomal recessive disease caused by the functional defect of alanine-glyoxylate aminotransferase that results in the overproduction of oxalate. It can be devastating especially for kidneys, leading to end-stage renal disease (ESRD) during the first 2 to 3 decades of life in most patients. Consequently, many PH1 patients need kidney transplantation. However, because PH1 is caused by a liver enzyme deficiency, the only cure of the metabolic defect is liver transplantation. Thus, current transplant strategies to treat PH1 patients with ESRD include dual liver–kidney transplantation. However, the morbidity and mortality associated with liver transplantation make these strategies far from optimal. Fortunately, a therapeutic revolution is looming. Indeed, innovative drugs are being currently tested in clinical trials, and preliminary data show impressive efficacy to reduce the hepatic over- production of oxalate. Hopefully, with these therapies, liver transplantation will no longer be necessary. However, some patients with progressing renal disease or those who will be diagnosed with PH1 at an advanced stage of chronic kidney disease will ultimately need kidney transplantation.
    [Show full text]